Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715676 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
A Phase 2 study, sponsored by Deltanoid Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
NCT00715676 is a Phase 2 study that has completed, run by Deltanoid Pharmaceuticals. The registered enrollment target is 157 participants.
The verdict
NCT00715676, a Phase 2 study, has completed, sponsored by Deltanoid Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
Study Summary
This study will evaluate the effect of a 1-year administration of the vitamin D analog 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density (BMD), safety, and tolerability.
Interventions
- DRUG Placebo
- DRUG DP001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00715676
The ClinicalTrials.gov registry entry for NCT00715676 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deltanoid Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00715676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00715676 about?
NCT00715676 is a clinical study titled "Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density". This study will evaluate the effect of a 1-year administration of the vitamin D analog 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density (BMD), safety, and tolerability.
What is the current status of trial NCT00715676?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2007-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00715676?
The interventions under investigation include: Placebo (DRUG), DP001 (DRUG).
Who is sponsoring clinical trial NCT00715676?
This trial is sponsored by Deltanoid Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.